Sermonix to Present ELAINE-3 Trial Poster at ASCO 2024

Sermonix Pharmaceuticals LLC, a biopharmaceutical firm focused on developing advanced treatments for metastatic breast cancer (mBC), has announced that it will present updates on its Phase 3 ELAINE-3 clinical trial at the upcoming American Society of Clinical Oncology (ASCO) annual meeting. This significant event will take place from May 31 to June 4, 2024, at McCormick Place in Chicago.

The ELAINE-3 study, an open-label, randomized, multicenter Phase 3 trial, is evaluating the safety and efficacy of combining lasofoxifene with abemaciclib, a CDK4/6 inhibitor produced by Eli Lilly and Company, in patients with ER+/HER2- breast cancer that has progressed to a locally advanced or metastatic stage and exhibits an ESR1 mutation. With the abstract numbered TPS1127 and the poster board designated as 101b, the presentation is scheduled for June 2, 2024, from 9 a.m. to noon CDT.

This trial, officially known as the third Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-3), involves 400 pre- and post-menopausal women globally. It compares the lasofoxifene and abemaciclib combination to the combination of fulvestrant and abemaciclib. The study is currently active and enrolling participants in various locations, including the United States, Canada, Europe, and Israel.

Dr. David Portman, Sermonix's founder and CEO, shared his enthusiasm for presenting at ASCO 2024, emphasizing the critical progress ELAINE-3 has achieved. He highlighted the promising anti-tumor activity that lasofoxifene has shown in previous studies against ESR1 mutations, noting potential benefits related to vaginal and sexual health quality of life. Dr. Portman expressed optimism that the ELAINE-3 trial will provide further insight into lasofoxifene's potential, bringing it closer to availability for patients.

Founded by Dr. David Portman, Sermonix Pharmaceuticals is a privately-held company that specializes in developing oncology products specifically for women. The company’s lead investigational drug, lasofoxifene, is currently under examination in the ELAINE-3 Phase 3 trial. The management team at Sermonix boasts extensive expertise across various facets of drug development, regulatory procedures, and commercialization.

Key team members include:
- Dr. Paul Plourde, Vice President of Oncology Clinical Development, who has decades of experience, particularly from his tenure at AstraZeneca.
- Dr. Barry Komm, Chief Scientific Officer, known for his specialization in nuclear receptor biology.
- Dr. Miriam Portman, Co-founder and Chief Operating Officer, who has a strong background in clinical trial management and patient recruitment.
- Elizabeth Attias, Chief Strategy and Development Officer, who brings vast experience in pharmaceutical commercialization.
- Dr. Simon Jenkins, Vice President of Operations, with over 30 years in global drug development leadership.

The non-executive chairman of the board, Dr. Anthony Wild, has held notable positions, including president of Parke-Davis Pharmaceuticals and Warner-Lambert’s Pharmaceutical Division.

Sermonix Pharmaceuticals continues to make strides in the realm of female-specific oncology treatments, driven by a team with formidable expertise and a clear vision for advancing therapeutic options for women battling metastatic breast cancer.